Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
There is a high unmet medical need for an anti-myeloma therapy for RRMM patients previously
treated with Lenalidomide and Bortezomib, due to poor prognosis.
This observational study focuses on the collection of data concerning the safe and optimal
usage of Pomalidomide, a new therapy option for RRMM patients, thereby increasing the
knowledge about optimal AE management. Beside this, further analysis of tolerability, dosage
and efficacy will be performed.
This knowledge could lead to a optimization of Pomalidomide usage and treatment.